Description: Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute.
Home Page: www.alaunos.com
TCRT Technical Analysis
8030 El Rio Street
Houston,
TX
77054
United States
Phone:
346 355 4099
Officers
| Name | Title |
|---|---|
| Mr. Kevin S. Boyle Sr. | CEO & Director |
| Mr. Michael Wong | VP of Fin. & Principal Accounting Officer |
| Mr. Abhishek Srivastava Ph.D. | VP of Technical Operations |
| Ms. Melinda Lackey | Sr. VP of Legal & Sec. |
| Dr. Drew C. Deniger Ph.D. | VP of R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0196 |
| Price-to-Sales TTM: | 50.8406 |
| IPO Date: | 2005-08-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |